RS20050047A - Indoline derivatives substituted in position 6,production and use thereof as medicaments - Google Patents

Indoline derivatives substituted in position 6,production and use thereof as medicaments

Info

Publication number
RS20050047A
RS20050047A YUP-2005/0047A YUP20050047A RS20050047A RS 20050047 A RS20050047 A RS 20050047A YU P20050047 A YUP20050047 A YU P20050047A RS 20050047 A RS20050047 A RS 20050047A
Authority
RS
Serbia
Prior art keywords
production
derivatives substituted
medicaments
indoline derivatives
salts
Prior art date
Application number
YUP-2005/0047A
Other languages
English (en)
Inventor
Gerald Jurgen Roth
Armin Heckel
Thorsten Lehmann-Lintz
Frank Hilberg
Grunt Ulrike Tontsch
Jacobus Van Meel
Original Assignee
Boehringer Ingelheim Pharma Gmbh.& Co.Kg.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10233366A external-priority patent/DE10233366A1/de
Priority claimed from DE10328533A external-priority patent/DE10328533A1/de
Application filed by Boehringer Ingelheim Pharma Gmbh.& Co.Kg., filed Critical Boehringer Ingelheim Pharma Gmbh.& Co.Kg.,
Publication of RS20050047A publication Critical patent/RS20050047A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ovaj pronalazak se odnosi na derivate indolinona, supstituisane u položaju 6, formule u kojoj R1 do R6 i X su kao što su definisani u Zahtevu 1, na njihove tautomere, enantiomere, dijastereomere, na njihove smeše i njihove soli, pre svega njihove fiziološki prihvatljive soli, koje poseduju korisne farmakološke karakteristike, posebno u inhibitornom dejstvu na različite receptorske tirozin kinaze i na proliferaciju endotelnih ćelija i različitih tumorskih ćelija, na lekove koji sadrže ova jedinjenja, na njihovu primenu i postupke za njihovo dobijanje.
YUP-2005/0047A 2002-07-23 2003-07-22 Indoline derivatives substituted in position 6,production and use thereof as medicaments RS20050047A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10233366A DE10233366A1 (de) 2002-07-23 2002-07-23 In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10328533A DE10328533A1 (de) 2003-06-24 2003-06-24 In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2003/007961 WO2004009547A1 (de) 2002-07-23 2003-07-22 In 6-stellung substituierte indolinonderivate, ihre herstellung und ihre verwendung als arzneimittel

Publications (1)

Publication Number Publication Date
RS20050047A true RS20050047A (en) 2007-09-21

Family

ID=30771725

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0047A RS20050047A (en) 2002-07-23 2003-07-22 Indoline derivatives substituted in position 6,production and use thereof as medicaments

Country Status (25)

Country Link
EP (1) EP1523473B1 (sr)
JP (1) JP4401291B2 (sr)
KR (2) KR20050052456A (sr)
CN (1) CN1318403C (sr)
AR (1) AR041188A1 (sr)
AU (2) AU2003254557B2 (sr)
BR (1) BR0312799A (sr)
CA (1) CA2493436C (sr)
DK (1) DK1523473T3 (sr)
EA (1) EA008623B1 (sr)
EC (1) ECSP055567A (sr)
ES (1) ES2409062T3 (sr)
HK (1) HK1081554A1 (sr)
HR (1) HRP20050069A2 (sr)
IL (1) IL166404A0 (sr)
MX (1) MXPA04012937A (sr)
MY (1) MY138141A (sr)
NO (1) NO20050937L (sr)
PE (1) PE20040701A1 (sr)
PL (2) PL397821A1 (sr)
RS (1) RS20050047A (sr)
SA (1) SA03240430B1 (sr)
TW (1) TWI343375B (sr)
UY (1) UY27903A1 (sr)
WO (1) WO2004009547A1 (sr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PE20061155A1 (es) * 2004-12-24 2006-12-16 Boehringer Ingelheim Int Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas
CA2605688A1 (en) 2005-04-28 2006-11-02 Boehringer Ingelheim International Gmbh Compounds for treating inflammatory diseases
WO2007057399A2 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
WO2009092580A1 (en) * 2008-01-25 2009-07-30 Boehringer Ingelheim International Gmbh Process for the manufacture of a 6-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene derivative
DK2238108T3 (da) * 2008-01-25 2012-10-15 Boehringer Ingelheim Int Saltformer af et 6-fluor-1,2-dihydro-2-oxo-3h-indol-3-yliden-derivat, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger indeholdende de samme
TW201011002A (en) 2008-07-29 2010-03-16 Boehringer Ingelheim Int New compounds
JP6263124B2 (ja) * 2012-10-17 2018-01-17 国立大学法人 岡山大学 化合物、その互変異性体、幾何異性体、乃至それらの塩、及びそれらの製造方法、抗菌剤、並びに感染症治療薬
JP6207625B2 (ja) 2012-12-06 2017-10-04 山東亨利醫藥科技有限責任公司 チロシンキナーゼ阻害剤としてのインドリノン誘導体
CN105461609B (zh) * 2015-12-25 2019-08-23 杭州新博思生物医药有限公司 一种尼达尼布的制备方法
CN114213396B (zh) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 一种吲哚-2-酮类化合物及其制备方法与用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243195T1 (de) * 1998-09-25 2003-07-15 Boehringer Ingelheim Pharma Neue substituierte indolinone mit einer inhibierenden wirkung auf verschiedene kinasen und cyclin/cdk-komplexe
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US6559173B1 (en) * 2001-09-27 2003-05-06 Allergan, Inc. 3-(heteroarylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
CA2461812C (en) * 2001-09-27 2011-09-20 Allergan, Inc. 3-(arylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors

Also Published As

Publication number Publication date
HK1081554A1 (en) 2006-05-19
JP2005533841A (ja) 2005-11-10
TW200413314A (en) 2004-08-01
CA2493436A1 (en) 2004-01-29
BR0312799A (pt) 2005-05-03
IL166404A0 (en) 2006-01-15
AU2010202845A1 (en) 2010-07-22
MXPA04012937A (es) 2005-05-16
ES2409062T3 (es) 2013-06-24
AU2003254557B2 (en) 2010-07-22
AR041188A1 (es) 2005-05-04
DK1523473T3 (da) 2013-06-03
ECSP055567A (es) 2005-04-18
EP1523473A1 (de) 2005-04-20
PL374879A1 (en) 2005-11-14
MY138141A (en) 2009-04-30
HRP20050069A2 (en) 2005-12-31
EA200500148A1 (ru) 2005-08-25
NO20050937L (no) 2005-02-21
WO2004009547A1 (de) 2004-01-29
UY27903A1 (es) 2004-02-27
CN1318403C (zh) 2007-05-30
KR20120003025A (ko) 2012-01-09
CN1668589A (zh) 2005-09-14
JP4401291B2 (ja) 2010-01-20
TWI343375B (en) 2011-06-11
PL397821A1 (pl) 2012-03-12
AU2003254557A1 (en) 2004-02-09
EP1523473B1 (de) 2013-02-27
PE20040701A1 (es) 2004-11-30
CA2493436C (en) 2011-11-08
EA008623B1 (ru) 2007-06-29
KR20050052456A (ko) 2005-06-02
SA03240430B1 (ar) 2008-03-23

Similar Documents

Publication Publication Date Title
SE0202463D0 (sv) Novel compounds
RS115004A (en) Novel thiophenylglycoside derivatives,methods for production thereof, medicaments comprising said compounds and use thereof
MY122357A (en) Indolinones having kinase inhibitory activity
GEP20074213B (en) Novel inhibitors of kinases
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
TNSN04199A1 (en) Acyl-4-carboxyphenylurea derivatives, processes for preparing them and their use
MY127956A (en) Substituted indolines which inhibit receptor tyrosine kinases
MX2007003104A (es) Nuevos derivados de ftalazinona, como inhibidores de cinasa aurora-a.
JO2353B1 (en) New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
TW200621715A (en) Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
TNSN06409A1 (en) Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
WO2004026829A3 (de) Heterocyclisch substituierte indolinone und deren verwendung als rezeptor-tyrosinkinasen inhibitoren
YU73900A (sh) Supstituisani indolinoni, njihovo pripremanje i njihova primena kao lekova
AU3864500A (en) Substituted aza-oxindole derivatives
RS20050047A (en) Indoline derivatives substituted in position 6,production and use thereof as medicaments
MXPA04000886A (es) Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos.
HK1051858A1 (en) Novel cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof.
WO2001027080A3 (de) In 5-stellung substituierte indolinone und ihre verwendung als kinase und cyclin-cdk-komplexe inhibitoren
IL165558A0 (en) N-benzoylureidocinnamate derivatives method for production and use thereof
WO2002010152A3 (de) Neue indolderivate und deren verwendung als arzneimittel
TNSN07006A1 (en) Novel heterocyclic compounds
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
BR0209901A (pt) Processos para a sìntese de derivados de 2,3-dihidro-1,4-dioxino-[2,3-f] quinolina
YU49902A (sh) Supstituisani derivati piperazina kao mtp inhibitori